| Absci is a generative artificial intelligence (AI) drug creation company utilizing deep learning and synthetic biology for therapeutic potential of proteins. Co. utilizes its integrated drug creation platform to identify drug targets and create biotherapeutic candidates. Co.'s Integrated Drug Creation platform combines: the data to train, in which its SoluPro technology constructs genetically-distinct cells; the AI to Create, which designs new therapeutic candidates using generative AI models; and the wet lab to validate, which supports its generative AI designs with its wet lab's throughput functional validation capabilities. The ABSI average annual return since 2021 is shown above.
The Average Annual Return on the ABSI average annual return since 2021 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether ABSI average annual return since 2021 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the ABSI average annual return calculation with any dividends reinvested as applicable (on ex-dates).